Universal Ibogaine Inc. is an emerging company in the pharmaceutical and mental health industries, focusing on innovative addiction treatment solutions. The company primarily aims to develop and commercialize Ibogaine-based therapies designed to confront addiction at its core. Ibogaine is a naturally occurring psychoactive compound derived from plants in the Apocynaceae family, found in West Africa. Universal Ibogaine leverages medical research and clinical trials to create safe, effective treatments, addressing deficiencies in traditional addiction therapy approaches.

The company spans healthcare and biotechnology sectors, contributing to both the scientific community and the wider public health domain. Universal Ibogaine collaborates with researchers and healthcare institutions to ensure regulatory compliance and efficacy in its treatment protocols. This positions the company as a potential disruptor in addiction therapy, offering novel, evidence-based alternatives. Universal Ibogaine Inc. plays a pivotal role in the market by tackling the growing global issue of opioid and substance addiction, with a mission to reimagine rehabilitation practices.